Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence Smith

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Annals of the New York Academy of Sciences|July 11, 2003
Multiple sclerosis and glutamateAnthony J Groom, Terence Smith, Lechoslaw Turski
European Journal of Pharmacology|November 4, 2008
The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinatoiron (III) chloride, (FeTPPS)Christopher Bolton, Gwen S Scott, Terence Smith, et al.
Brain Pathology (Zurich, Switzerland)|October 11, 2007
Glutamate receptor expression in multiple sclerosis lesionsJia Newcombe, Alim Uddin, Rosamund Dove, et al.
Journal of Neuroimmunology|April 19, 2002
Altered expression of glutamate transporters in experimental autoimmune encephalomyelitisMakoto Ohgoh, Takahisa Hanada, Terence Smith, et al.
Journal of Neuroimmunology|May 10, 2005
ADAM-17 and TIMP3 protein and mRNA expression in spinal cord white matter of rats with acute experimental autoimmune encephalomyelitisJonnie Plumb, Alison K Cross, Jessica Surr, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Martin S Weber, et al.
Bioresource Technology|February 11, 2014
Direct measurement and characterization of active photosynthesis zones inside wastewater remediating and biofuel producing microalgal biofilmsHans C Bernstein, Maureen Kesaano, Karen Moll, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 21, 2015
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosisLudwig Kappos, Nicola De Stefano, Mark S Freedman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Annals of the New York Academy of Sciences|July 11, 2003
Multiple sclerosis and glutamateAnthony J Groom, Terence Smith, Lechoslaw Turski
European Journal of Pharmacology|November 4, 2008
The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinatoiron (III) chloride, (FeTPPS)Christopher Bolton, Gwen S Scott, Terence Smith, et al.
Brain Pathology (Zurich, Switzerland)|October 11, 2007
Glutamate receptor expression in multiple sclerosis lesionsJia Newcombe, Alim Uddin, Rosamund Dove, et al.
Journal of Neuroimmunology|April 19, 2002
Altered expression of glutamate transporters in experimental autoimmune encephalomyelitisMakoto Ohgoh, Takahisa Hanada, Terence Smith, et al.
Journal of Neuroimmunology|May 10, 2005
ADAM-17 and TIMP3 protein and mRNA expression in spinal cord white matter of rats with acute experimental autoimmune encephalomyelitisJonnie Plumb, Alison K Cross, Jessica Surr, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Martin S Weber, et al.
Bioresource Technology|February 11, 2014
Direct measurement and characterization of active photosynthesis zones inside wastewater remediating and biofuel producing microalgal biofilmsHans C Bernstein, Maureen Kesaano, Karen Moll, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 21, 2015
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosisLudwig Kappos, Nicola De Stefano, Mark S Freedman, et al.
Pageof 1